Place value of PET at ENT-tumors;Stellenwert der PET bei Kopf-Hals-Tumoren

Laryngo- Rhino- Otologie

Volumn 83, Issue 6, 2004, Pages 391-408

  Reske, Seven N ^a   Dankerl, A ^a   Glatting, G ^a   Mottaghy, F M ^a   Blumstein, N M ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

ENT malignomas; Oncology; PET

Indexed keywords

FLUORODEOXYGLUCOSE; THYMIDINE;

AMINO ACID METABOLISM; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; CELL PROLIFERATION; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; HEAD AND NECK TUMOR; HUMAN; HYPOXEMIA; IMAGE ANALYSIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN METABOLISM; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR GROWTH;

AMINO ACIDS; BLOOD GLUCOSE; ENERGY METABOLISM; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MOLECULAR PROBE TECHNIQUES; NEOPLASM PROTEINS; NEOPLASM STAGING; OTORHINOLARYNGOLOGIC NEOPLASMS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 3042664869     PISSN: 09358943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-814367     Document Type: Review

References (62)

1. Adams S, Baum RP, Stuckensen T, Bitter K, Hor G. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 1998; 25: 1255-1260
2. Ambrosch P, Kron M, Fischer G, Brinck U. Micrometastases in carcinoma of the upper aerodigestive tract: detection, risk of metastasizing, and prognostic value of depth of invasion. Head Neck 1995; 17: 473-479
3. Bading JR, Kan-Mitchell J, Conti PS. System A amino acid transport in cultured human tumor cells: implications for tumor imaging with PET. Nucl Med Biol 1996; 23: 779-786
4. Barrington SF, Maisey MN. Skeletal Muscle Uptake of Fluorine-18-FDG: Effect of Oral Diazepam. J Nucl Med 1996; 37: 1127-1129
5. Barthel H, Cleij M, Collingridge D et al. 3′-Deoxy-3′-[18F] Fluorothymidine as a new marker for monitoring tumor response to anti-proliferate therapy in vivo with positron emission tomography. Cancer Res 2003; 63: 3791-3798
6. Benchaou M, Lehmann W, Slosman DO et al. The role of FDG-PET in the preoperative assessment of N-staging in head and neck cancer. Acta Otolaryngold (Stockh) 1996; 116: 332-335
7. Bergstrom M, Lundqvist H, Ericson K et al. Comparison of the accumulation kinetics of L-(methyl-11C)-methionine and D-(methyl-11C)-methionine in brain tumors studied with positron emission tomography. Acta Radiol 1987; 28: 225-229
8. Braams J, Pruim J, Nikkels P, Roodenburg J, Vaalburg W, Vermey A. Nodal Spread of Squamous Cell Carcinoma of the Oral Cavity Detected with PET-Tyrosine, MRI and CT. J Nucl Med 1996; 37: 897-901
9. Braams JW, Pruim J, Freling NJM et al. Detection of lymph node metastases of squamous-cell cancer of the head and neck with FDG-PET and MRI. J Nucl Med 1995; 36: 211-216
10. Buck A, Schirrmeister H, Hetzel M et al. F-18-FLT-PET for non-invasive assessment of proliferation in pulmonary nodules. Cancer research 2002; 62: 3331-3334
11. Buck AK, Halter G, Schirrmeister H et al. Imaging Proliferation in Lung Tumors with PET: 18F-FLT Versus 18F-FDG. J Nucl Med 2003; 44: 1426-1441
12. Changlai SP, Kao CH, Chieng PU. 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography of head and neck in patients with nasopharyngeal carcinomas. Oncology Report 1997; 4: 1331-1334
13. Chesnay E, Babin E, Constans JM et al. Early Response to Chemotherapy in Hypopharyngeal Cancer: Assessment with 11C-Methionine PET, Correlation with Morphologic Response, and Clinical Outcome. J Nucl Med 2003; 44: 526-532
14. Choi Y, Brunken RC, Hawkins RA et al. Factors affecting myocardial 2-[F-18]fluoro-2-deoxy-D-glucose uptake in positron emission tomography studies of normal humans. Eur J Nucl Med 1993; 20: 308-318
15. Collins BT, Gardner LJ, Verma AK, Lowe VJ, Dunphy FR, Boyd JH. Correlation of fine needle aspiration biopsy and fluoride-18 fluorodeoxyglucose positron emission tomography in the assessment of locally recurrent and metastatic head and neck neoplasia. Acta Cytol 1998; 42: 1325-1329
16. Czernin J, Phelps ME. Positron emission tomography scanning: current and future applications. Annu Rev Med 2002; 53: 89-112
17. De Boer J, Pruim J, Burlage F et al. Therapy evaluation of laryngeal carcinomas by tyrosine-PET. Head Neck 2003; 25: 634-644
18. Di-Martino E, Nowak B, Hassan HA et al. Diagnosis and staging of head and neck cancer: a comparison of modern imaging modalities (positron emission tomography, computed tomography, color-coded duplex sonography) with panendoscopic and histopathologic findings. Arch Otolaryngol Head Neck Surg 2000; 126: 1457-1461
19. Di-Martino E, Nowak B, Krombach GA et al. Ergebnisse der prätherapeutischen Lymphknoten-diagnostik bei Kopf-Hals-Tumoren. Klinische Wertigkeit der 18FDG-Positronen-Emissions-Tomographie (PET). Laryngorhinootologie 2000; 79: 201-206
20. Glatz S, Kotzerke J, Moog F, Sandherr M, Heimpel H, Reske S. Vortäuschung eines mediastinalen Non-Hodkin-Lymphomrezidivs durch diffuse Thymushyperplasie im 18F-FDG-PET. Fortschr Röntgenstr 1996; 165: 309-310
21. Greven KM, Williams DW 3rd, Keyes JW Jr, McGuirt WF, Watson NE Jr, Case LD. Can positron emission tomography distinguish tumor recurrence from irradiation sequelae in patients treated for larynx cancer? [see comments]. Cancer J Sci Am 1997; 3: 353-357
22. Haenggeli CA, Dulguerov P, Slosman D et al. Role de la tomographie par emission de positrons avec le 18-fluoro-deoxyglucose (PET-FDG) dans la detection precoce d'une non-sterilisation tumorale des carcinomes bucco-pharyngo- larynges. Schweiz Med Wochenschr Suppl 2000; 116: 8S-11S
23. Hany T, Gharehpapahg E, Kamel E, Buck A, Himms-Hagen J, von Schulthess GK. Brown adipose tissue: a factor to consider in symmetrical tracer uptake in the neck and upper chest region. Eur J Nucl Med 2002; 29: 1393-1398
24. Jager P, Vaalburg W, Pruim J, de Vries E, Langen K, Piers D. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 2001; 42: 432-445
25. Jose J, Coatesworth AP, McLennan K. Cervical metastases in upper aerodigestive tract squamous cell carcinoma: histopathologic analysis and reporting. Head Neck 2003; 25: 194-197
26. Kao CH, Chang Lai SP, Chieng PU, Yen RF, Yen TC. Detection of recurrent or persistent nasopharyngeal carcinomas after radiotherapy with 18-fluoro-2-deoxyglucose positron emission tomography and comparison with computed tomography. J Clin Oncol 1998; 16: 3550-3555
27. Kau RJ, Alexiou C, Laubenbacher C, Werner M, Schwaiger M, Arnold W. Lymph node detection of head and neck squamous cell carcinomas by positron emission tomography with fluorodeoxyglucose F 18 in a routine clinical setting. Archives of Otolaryngology - Head and Neck Surgery 1999; 125: 1322-1328
28. Kau RJ, Alexiou C, Stimmer H, Arnold W. Diagnostic procedures for detection of lymph node metastases in cancer of the larynx. ORLJ Otorhinolaryngol Relat Spec 2000; 62: 199-203
29. Kitagawa Y, Nishizawa S, Sano K et al. Prospective Comparison of 18F-FDG PET with Conventional Imaging Modalities (MRI, CT, and 67Ga Scintigraphy) in Assessment of Combined Intra-arterial Chemotherapy and Radiotherapy for Head and Neck Carcinoma. J Nucl Med 2003; 44: 198-206
30. Kracht L, Friese M, Herholz K et al. Methyl-[11C]-1-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging 2003; 303: 868-873
31. Kresnik E. F-18-Fluorodeoxy-Glukose-Positronenemissionstomographie in der Abklärung von Tumoren im HNO-Bereich: eigene Ergebnisse und Literaturübersicht. Wien Med Wochenschr 2002; 152: 259-264
32. Kunkel M, Kuffner HD, Reichert TE, Benz P, Forster GJ, Wagner W. [18F]-2-Fluordeoxyglukose-PET. Perspektiven der Sekundarprophylaxe des Mundhöhlenkarzinoms. Mund Kiefer Gesichtschir 2000; 4: 105-110
33. Langen KJ, Braun U, Rota Kops E et al. The Influence of Plasma Glucose Levels on Fluorine-18-Fluorodeoxyglucose Uptake in Bronchial Carcinomas. J Nucl Med 1993; 34: 355-359
34. Lapela M, Eigtved A, Jyrkkio S et al. Experience in qualitative and quantitative FDG PET in follow-up of patients with suspected recurrence from head and neck cancer. Eur J Cancer 2000; 36: 858-867
35. Laubenbacher C, Saumweber D, Wagner Manslau C et al. Comparison of Fluorine-18-Fluorode-oxyglucose PET, MRI and Endoscopy for Staging Head and Neck Squamous-Cell Carcinomas. J Nucl Med 1995; 36: 1747-1757
36. Lewis JS, McCarthy DW, McCarthy TJ, Fujibayashi Y, Welch MJ. Evaluation of 64-Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med 1999; 40: 177-183
37. Lindholm P, Minn H, Leskinen Kallio S, Bergmann J, Ruotsalainen U, Joensuu H. Influence of the Blood Glucose Concentration on FDG Uptake in Cancer - A PET Study. J Nucl Med 1993; 34: 1-6
38. Lowe V, Stack B. PET Imaging in Head Neck Cancer. In: Valk Pet al. (eds). Positron Emission Tomography - Basic Science and Clinical Practice. London: Springer-Verlag, 2003: 535-546
39. Lowe VJ, Boyd JH, Dunphy FR et al. Surveillance for recurrent head and neck cancer using positron emission tomography. J Clin Oncol 2000; 18: 651-658
40. McGuirt WF, Greven KM, Keyes JW Jr, Williams DW 3rd, Watson N. Laryngeal radionecrosis versus recurrent cancer: a clinical approach. Ann Otol Rhinol Laryngol 1998; 107: 293-296
41. McGuirt WF, Williams DW, Keyes JW et al. A comparative diagnostic study of head and neck nodal metastases using positron emission tomography. Laryngoscope 1995; 105: 373-374
42. Myers LL, Wax MK, Nabi H, Simpson GT, Lamonica D. Positron emission tomography in the evaluation of the NO neck. Laryngoscope 1998; 108: 232-236
43. Narayanan T, Said S, Mukherjee J et al. A comparative study on the uptake and incorporation of radiolabeled methionine, choline and fluorodeoxyglucose in human astrocytoma. Mol Imaging Biol 2002; 4: 147-156
44. Papac RJ. Distant metastases from head and neck cancer. Cancer 1984; 53: 342-345
45. Patel PM, Alibazoglu H, Ali A, Fordham E, LaMonica G. Normal thymic uptake of FDG on PET imaging. Clin Nucl Med 1996; 21: 772-775
46. Phelps ME. Positron emission tomography provides molecular imaging of biological processes. Proc Nati Acad Sci U S A 2000; 97: 9226-9233
47. Popperl G, Lang S, Dagdelen O et al. Korrelation von FDG-PET und MRT/CT mit der Histopathologie in Primärdiagnostik, Lymphknotenstaging und Rezidivdiagnostik von Kopf-Hals-Tumoren. Rofo Fortschr Geb Röntgenstr Neuen Bildgeb Verfahr 2002; 174: 714-720
48. Rasey JS, Hofstrand PD, Chin LK, Tewson TJ. Characterization of [18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia. J Nucl Med 1999; 40: 1072-1079
49. Rege S, Maass A, Chaiken L et al. Use of Positron Emission Tomography with Fluorodeoxyglucose in Patients with Extracranial Head and Neck Cancers. Cancer 1994; 73: 3047-3058
50. Reske SN, Kotzerke J. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000. Eur J Nucl Med 2001; 28: 1707-1723
51. Riess H, Wust P. Tumoren des Kopf- und Halsbereiches. In: Wilmanns W, Huhn D, Wilms K (eds). Internistische Onkologie. Stuttgart, New York: Georg Thieme Verlag, 1994: 572-583
52. Schmoll H, Höffken K, Possinger K. Kompendium Internistische Onkologie, Standards in Diagnostik und Therapie. Berlin, Heidelberg: Springer Verlag, 2002
53. Stöcklin G, Pike V. Radiopharmaceuticals for Positron Emission Tomography - Methodological Aspects. Developments in Nuclear Medicine, ed. Cox PH. Vol. 24. Dordrecht/Boston/London: Kluwer Academic Publishers, 1993
54. Stoeckli SJ, Steinert H, Pfaltz M, Schmid S. Is there a role for positron emission tomography with 18F-fluorodeoxyglucose in the initial staging of nodal negative oral and oropharyngeal squamous cell carcinoma? Head Neck 2002; 24: 345-349
55. Stokkel MP, Terhaard CH, Hordijk GJ, van-Rijk PP. The detection of local recurrent head and neck cancer with fluorine-18 fluorodeoxyglucose dual-head positron emission tomography. Eur J Nucl Med 1999; 26: 767-773
56. Terhaard CH, Bongers V, van-Rijk PP, Hordijk GJ. F-18-fluoro-deoxy- glucose positron-emission tomography scanning in detection of local recurrence after radiotherapy for laryngeal/pharyngeal cancer. Head Neck 2001; 23: 933-941
57. Vallabhajosula S. Radiopharmaceuticals in oncology. In: Khalkhali I, Maublant J, Goldsmith S (eds). Nuclear Oncology - Diagnosis and Therapy. Philadelphia: Lippincott Williams & Wilkins, 2001: 31-72
58. Warburg O. The metabolism of t-umors. New York: Richard R. Smith Inc, 1931
59. Weissleder P, Molecular imaging: exploring the next frontier [editorial]. Radiology 1999; 212: 609-614
60. Wittekind C, Meyer H, Bootz F. TNM-Klassifikation maligner Tumoren. Berlin, Heidelberg: Springer Verlag, 2003
61. Wong WL, Chevretton EB, McGurk M et al. A prospective study of PET-FDG imaging for the assessment of head and neck squamous cell carcinoma. Clin Otolaryngol 1997; 22: 209-214
62. Zhu Z, Chou C, Yen TC, Cui R. Elevated F-18 FDG uptake in laryngeal muscles mimicking thyroid cancer metastases. Clin Nucl Med 2001; 26: 689-691